UK-based healthcare technology company Huma announced it secured more than $80 million in a Series D funding round, bringing its total raise to over $300 million.
New and existing investors, including AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures, participated in the round.
The company, which creates applications that integrate patient data from hospital databases, mobile devices, and wearables for providers, also announced the launch of its new product, Huma Cloud Platform.
Huma Cloud is a no-code platform that allows developers to create disease management tools using a library of pre-built modules and device connectivity capabilities. The cloud-agnostic framework also offers APIs and integration capabilities and can host and deploy predictive and diagnostic AI algorithms.
“We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics,” Dr. Juergen Eckhardt, EVP, head of Leaps by Bayer and pharmaceuticals business, development and licensing, said in a statement.
“With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.”
Value-based cancer care platform Thyme Care garnered $60 million in Series B financing, bringing its total raise to over $80 million.
Town Hall Ventures and Foresite Capital co-led the round with participation from existing investors Andreessen Horowitz Bio + Health, Casdin Capital, Frist Cressey Ventures and AlleyCorp.
David Whelan, cofounder and general partner at Town Hall Ventures, and Elizabeth Canis, executive advisor to Foresite Capital, who previously held executive positions at Elevance and UnitedHealthcare, will join Thyme’s board of directors.
The company will use the funds to expand its network of oncology partners and cancer care support services.
“The U.S. healthcare system is notoriously fragmented, leaving cancer patients hanging in the balance. We invest in companies that are changing the narrative by putting the patient first and are shifting the industry toward value-based care,” Whelan said in a statement.
“Primary care and kidney care have paved the way for this transformation, and after extensively studying the landscape, we firmly believe Thyme Care is the only company with the expertise and technology to enable value-based cancer care. We look forward to helping them accelerate this mission.”
Implantable sacral neuromodulation company Neuspera Medical, Inc., closed its Series D funding round with $23 million.
Vertex Ventures HC and Treo Ventures led the round with participation from Windham Venture Partners, Action Potential Venture Capital, Olympus Innovation Ventures and another strategic investor.
The company makes the ultra-miniaturized Neuspera Implantable Sacral Neuromodulation System, which is designed to help patients control urinary incontinence, a symptom of an overactive bladder.
The Calif.-based company will use the funds to make its way through the FDA premarket approval process.
“As a partner of choice for innovators in urology, we are thrilled to invest in the Neuspera team as they bring the Neuspera System through FDA approval and to the market,” Gabriela Kaynor, president of Olympus Innovation Ventures and chief strategy officer at Olympus Corporation.
“Based on critical unmet market need and patient demand, changes in society guidelines, and positive feedback from patients and physicians in clinical trials, we are excited to invest in the Neuspera team as they build their innovative Neuspera System for OAB.”
The HIMSS AI in Healthcare Forum is scheduled to take place September 5-6 in Boston. Learn more and register.
